The Oncology Institute, Inc. $TOI Shares Purchased by Josh Arnold Investment Consultant LLC

Josh Arnold Investment Consultant LLC raised its stake in shares of The Oncology Institute, Inc. (NASDAQ:TOI) by 1,104.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,459,809 shares of the company’s stock after acquiring an additional 2,255,559 shares during the quarter. Oncology Institute makes up 4.8% of Josh Arnold Investment Consultant LLC’s portfolio, making the stock its 5th largest holding. Josh Arnold Investment Consultant LLC’s holdings in Oncology Institute were worth $8,757,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in TOI. Kanen Wealth Management LLC acquired a new stake in shares of Oncology Institute in the 3rd quarter valued at $6,421,000. Marshall Wace LLP acquired a new stake in shares of Oncology Institute during the 2nd quarter worth about $3,028,000. Geode Capital Management LLC lifted its holdings in Oncology Institute by 231.7% during the 2nd quarter. Geode Capital Management LLC now owns 1,279,443 shares of the company’s stock valued at $2,623,000 after purchasing an additional 893,696 shares during the last quarter. UBS Group AG lifted its holdings in Oncology Institute by 151.2% during the 3rd quarter. UBS Group AG now owns 1,055,862 shares of the company’s stock valued at $3,685,000 after purchasing an additional 635,489 shares during the last quarter. Finally, Millennium Management LLC lifted its holdings in Oncology Institute by 134.8% during the 3rd quarter. Millennium Management LLC now owns 951,001 shares of the company’s stock valued at $3,319,000 after purchasing an additional 545,992 shares during the last quarter. Institutional investors and hedge funds own 36.86% of the company’s stock.

Oncology Institute Stock Up 0.2%

Shares of NASDAQ:TOI opened at $5.26 on Friday. The firm has a market cap of $519.90 million, a P/E ratio of -14.22 and a beta of 0.37. The Oncology Institute, Inc. has a 12 month low of $2.02 and a 12 month high of $5.57. The company’s 50-day moving average price is $4.15 and its two-hundred day moving average price is $3.51.

Oncology Institute (NASDAQ:TOI) last announced its earnings results on Thursday, May 7th. The company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.05. The company had revenue of $147.44 million during the quarter, compared to the consensus estimate of $142.10 million. As a group, equities analysts predict that The Oncology Institute, Inc. will post -0.17 earnings per share for the current fiscal year.

Insider Activity at Oncology Institute

In other news, Director Mohit Kaushal sold 38,433 shares of the business’s stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $3.50, for a total transaction of $134,515.50. Following the completion of the sale, the director owned 172,583 shares in the company, valued at $604,040.50. The trade was a 18.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Jorey Chernett bought 12,000 shares of Oncology Institute stock in a transaction dated Thursday, June 4th. The stock was acquired at an average cost of $4.75 per share, for a total transaction of $57,000.00. Following the purchase, the insider directly owned 10,579,858 shares in the company, valued at approximately $50,254,325.50. The trade was a 0.11% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders purchased 225,500 shares of company stock valued at $787,045 and sold 119,170 shares valued at $461,183. 4.40% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several brokerages have weighed in on TOI. B. Riley Financial upped their price objective on shares of Oncology Institute from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Friday, March 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oncology Institute in a research note on Monday, April 20th. BTIG Research boosted their target price on Oncology Institute from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, June 8th. Finally, Needham & Company LLC increased their price target on Oncology Institute from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Wednesday. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $7.75.

Oncology Institute Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.